1-3 of 3
Andres Gutierrez, MD
Close
Sort by
Journal Articles

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Raymond Perez, MD, Rachid Baz, MD, Paul G. Richardson, Kenneth C. Anderson, MD, Peter Sabbatini, PhD, Clifford Dilea, Pina M. Cardarelli, PhD, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, Pamela S. Becker, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3483.
https://doi.org/10.1182/blood.V124.21.3483.3483
Published: 2014
Journal Articles

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD PhD, James M. Foran, MD, Jessica K. Altman, MD, Abdulraheem Yacoub, MD MB, Januario E. Castro, MD, Peter Sabbatini, PhD, Clifford Dilea, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, B. Douglas Smith, MD
Journal: Blood
Blood (2014) 124 (21): 386.
https://doi.org/10.1182/blood.V124.21.386.386
Published: 2014
Journal Articles

Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM).

Ruben Niesvizky, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., William Bensinger, MD, Melissa Alsina, MD, Nashat Gabrail, MD, Andres Gutierrez, MD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2009) 114 (22): 304.
https://doi.org/10.1182/blood.V114.22.304.304
Published: 2009